Thermo Fisher Scientific

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
January 23, 2018

Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

[vc_row][vc_column][vc_column_text]The Food and Drug Administration recently announced the first ever approval of a directly administered gene therapy in the United States. Spark Therapeutics one-time gene therapy […]
May 23, 2017

Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon

[vc_row][vc_column][vc_column_text] Dutch Contract Development & Manufacturing Organisation Patheon has been acquired by Thermo Fisher Scientific in a $7.2B deal. The acquisition, which includes the assumption of […]
April 12, 2017

GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

[vc_row][vc_column][vc_column_text]GE Healthcare recently announced the acquisition of British cryogenic processing company Asymptote for an undisclosed price, strengthening its cell therapy portfolio with technologies designed to enable […]
March 2, 2017

The Antibody Quality Conundrum: Abcam Ahead of the Curve with Knockout Validation

[vc_row][vc_column][vc_column_text] In September 2016 the International Working Group for Antibody Validation (IWGAV) finally announced their five conceptual pillars, outlining recommendations to mitigate the antibody specificity and […]